Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

624 results about "Immunoconjugate" patented technology

Immunoconjugates are antibodies conjugated (joined) to a second molecule, usually a toxin, radioisotope or label. These conjugates are used in immunotherapy and to develop monoclonal antibody therapy as a targeted form of chemotherapy when they are often known as antibody-drug conjugates.

Dimeric immunoconjugates for use in treating cancers and methods of use

This disclosure relates to dimeric immunoconjugates for use in treating cancer generally and to dimeric immunoconjugates that bind human sperm protein 17 (Sp17) specifically. A dimeric immunoconjugate of this disclosure generally comprises a first monomeric antibody that carries a first payload and a second monomeric antibody that carries a second payload, wherein the first payload and the second payload are different. Such dimeric immunoconjugates advantageously allow the simultaneous delivery of two chemotherapeutics to a cancer cell, which allows for synergistic antineoplastic activity.
Owner:MEDICOVESTOR INC

Antibodies and antibody-drug conjugates thereof

Disclosed are antibodies and antigen binding fragments thereof, and immunoconjugates comprising the antibodies and antigen binding fragments thereof. Also disclosed are compositions and uses of the antibodies and immunoconjugates for treatment of cancers.
Owner:MULTITUDE THERAPEUTICS INC

Antibody conjugates and fusion proteins

The present invention relates to immunoglobulins, such as immunoconjugates, comprising an ActRII receptor antibody and an agonistic GLP-1 molecule, such as agonistic GLP-1 peptide. Such constructs are useful in the treatment of numerous diseases and disorders, including metabolic disorders, such as obesity, diabetes and others.
Owner:SIXPEAKS BIO AG

Combination therapies for the treatment of cancer

Provided are methods of treating a cellular proliferative disorder (e.g., cancer) comprising administering: (a) an anti-human PD-1 antibody or antigen binding fragment thereof; and (b) an Immunoconjugate of Formula (I) : wherein: Ab is an antibody that binds to Trop-2; and n is an integer from 1 to 10. Also disclosed are therapeutic combinations and kits containing such agents for the treatment of cancers.
Owner:MERCK SHARP & DOHME LLC +1

Antibody specific to CD123 and antibody-drug conjugate, and use of the same

To provide an antibody specific to CD123 and an antibody-drug conjugate, and use thereof.SOLUTION: The present invention provides an antibody that specifically binds to CD123. The present invention further relates to an immune conjugate (e.g., antibody drug conjugate or ADC) including the antibody, nucleic acid encoding the antibody, and a method for obtaining the antibody. The present invention further relates to a therapeutic method regarding use of the antibody and ADC for treating symptoms related to a cell expressing CD123 (e.g., cancer or autoimmune disease).SELECTED DRAWING: Figure 1
Owner:PFIZER INC

Monoclonal antibodies and bispecific antibody against c-met

The present application relates to an antibody capable of specifically binding to c-Met or antigen-binding fragment thereof, and an immunoconjugate, a pharmaceutical composition and a multispecific molecule comprising the same. The present application further relates to the use of the antibody specifically binding to c-Met or an antigen-binding fragment thereof and the multispecific molecule. Compared with the control antibody, the bispecific antibody or defucosylated bispecific antibody of the present application can block HGF-dependent TKI resistance; block the proliferation and migration of tumor cells induced by HGF, induce ADCC effect, and inhibit tumor growth in vivo.
Owner:BIOTHEUS INC

Antibody linker conjugates

Described herein are novel linkers for use with immunoconjugates to connect a targeting moiety to a radiochelator moiety without impairing the functionality of either. The linkers of the invention may provide a stable linkage in circulation, permit fast total body clearance including from organs such as the liver, high tumor uptake and high tumor-to-normal-organ radiation exposure (for example, in the liver and kidneys). The immunoconjugates can be used to deliver radioisotopes including alpha and beta emitters for the treatment of tumors or cancer.
Owner:ABDERA THERAPEUTICS INC

Phosphatidylinositol proteoglycan 3 antibodies and related methods

The present disclosure provides amino acid sequences (e.g., antibodies) capable of binding to glypican 3 protein (GPC3). The present disclosure relates to antigen binding fragments of GPC3 antibodies; conjugates of a GPC3 antibody, including an immunoconjugate; bispecific antibodies comprising a GPC3 antibody and related compositions and formulations. The disclosure also relates to methods of treating GPC3-related diseases, disorders and conditions, including cell proliferative diseases, such as cancer, more particularly liver cancer, using these sequences, such as GPC3 antibodies and antigen-binding fragments thereof.
Owner:JIECO BIOPHARMACEUTICALS

Antibodies and immunoconjugates for individualized therapy

The disclosure relates to avian Immunoglobulin Y (IgY) antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind to an antigen (such as a human tumor associated antigen), as well as methods of making and using said antibodies and antigen binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.
Owner:NANOCARE TECHNOLOGIES INC

Interleukin-2 mutant and fusion protein thereof

Disclosed are a new interleukin-2 (IL-2) mutant protein and the use thereof. Compared with wild-type IL-2, the IL-2 mutant protein has improved properties, such as an improved IL-2 receptor binding property and improved druggability. Also provided are a fusion protein, dimer and immunoconjugate comprising the IL-2 mutant protein, nucleic acids encoding the IL-2 mutant protein, the dimer and the immunoconjugate, and a vector and host cell comprising the nucleic acid. Further provided are methods for preparing the IL-2 mutant protein, the fusion protein, the dimer and the immunoconjugate, a pharmaceutical composition containing same, and the therapeutic use thereof.
Owner:FORTVITA BIOLOGICS (SINGAPORE) PTE LTD

Anti-PD-1 antibody-attenuated IL-2 immunoconjugates and uses thereof

Disclosed herein are modified human interleukin-2 (hIL-2) proteins, human antibody molecules or antigen-binding fragments thereof that immunospecifically bind to human programmed cell death protein-1 (hPD-1), and immunoconjugates comprising the same.
Owner:CEPHALON INC

Anti-TSLP antibodies and uses thereof

Provided are anti-TSLP antibodies or antigen-binding fragments thereof. Provided is also related to polynucleotides encoding the antibodies or antigen-binding protein constructs, and expression vectors and host cells comprising the same. Also provided are immunoconjugates, pharmaceutical compositions and medicaments, as well as uses thereof for treating diseases or disorders.
Owner:INNOVENT BIOLOGICS (SUZHOU) CO LTD

Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011 / 0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.
Owner:BRISTOL MYERS SQUIBB CO

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti-LAG-3 antibody is co-administered with at least one additional immunostimulatory antibody, is also provided.
Owner:ER SQUIBB & SONS LLC

Monoclonal antibodies which bind thymic stromal lymphopoietin (TSLP), encoding polynucleotides thereof and methods of use thereof to treat diseases

Disclosed is an isolated monoclonal antibody that specifically binds human TSLP, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present disclosure further provides a bispecific molecule, an immunoconjugate, a CAR-immune cell, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-TSLP antibody of the disclosure.
Owner:BIOSION INC

Combination therapies for the treatment of metastatic non-small cell lung cancer

The present disclosure relates to methods of treating metastatic non-small cell lung cancer in a patient, said methods comprising administering to the patient: (a) an anti-human PD-1 antibody or antigen binding fragment thereof; and (b) an Immunoconjugate of Formula (I) wherein: Ab is an antibody that binds to Trop-2; and n is an integer from 1 to 10.
Owner:MERCK SHARP & DOHME LLC

Immunoconjugates and methods

Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.Ab-[S-L1-L2-L3-L4-L5-L6-L7-D]n   (I)
Owner:IMMUNOME INC

Immunoconjugates

The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
Owner:F HOFFMANN LA ROCHE INC

Anti-PD-1 antibody-attenuated il-2 immunoconjugates and uses thereof

Disclosed herein are modified human interleukin-2 (hIL-2) proteins, human antibody molecules, or antigen-binding fragments thereof, that immunospecifically bind to human programmed cell death protein-1 (hPD-1), and immunoconjugates comprising the same.
Owner:CEPHALON INC

Immunoconjugates and methods

Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.Ab-[S-L1-L2-L3-L4-L5-L6-L7-D]n   (I)
Owner:IMMUNOME INC

Interleukin-2 and use thereof

The present invention relates to a novel interleukin-2 (IL-2) mutant protein and use thereof. In particular, the present invention relates to an IL-2 mutant protein with reduced IL-2Rα receptor binding ability and / or increased IL-2Rβ receptor binding ability compared with the wild-type IL-2. The present invention further provides a fusion protein and an immunoconjugate comprising the IL-2 mutant protein, a nucleic acid encoding the IL-2 mutant protein, and a vector and a host cell comprising the nucleic acid. The present invention further provides a method for preparing the IL-2 mutant protein, a pharmaceutical composition comprising the IL-2 mutant protein, and therapeutic use of the mutant protein.
Owner:INNOVENT BIOLOGICS (SUZHOU) CO LTD

Antibody-Drug Conjugates Against EPH Receptor A5 (Epha5) for Treatment of Carcinoma

The present invention relates to immunoconjugates specific for human EPH receptor A5 (EphA5), methods of treatment of cancers (e.g., carcinomas including squamous cell carcinoma, and colorectal cancer) using said immunoconjugates, and related pharmaceutical compositions of said immunoconjugates.
Owner:MBRACE THERAPEUTICS INC

Immunoconjugates and methods

Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.Ab-[S-L1-L2-L3-L4-L5-L6-L7-D]n   (I)
Owner:IMMUNOME INC

Antibody-drug conjugate, and pharmaceutical composition thereof, preparation therefor and use thereof

An immunoconjugate and a use thereof, an immunoconjugate as represented by formula I, or a tautomer, a mesomer, a racemate, an enantiomer, a diastereoisomer, or a pharmaceutically acceptable salt or hydrate thereof, and a use thereof as an anti-tumor drug.
Owner:SHANGHAI VISONPHARMA CO LTD

Targeting TROP2xPD-L1 bispecific antibody drug conjugate as well as preparation method and application thereof

The invention relates to an antibody specifically binding to TROP2 or an antigen binding fragment thereof. The invention also encompasses VHH antibodies or heavy chain antibodies that specifically bind to PD-L1. The invention further relates to a bispecific antibody which is constructed on the basis of the TROP2 antibody and the PD-L1 antibody and is specifically combined with the TROP2 and the PD-L1. The invention also encompasses immunoconjugates constructed based on the antibody molecules, such as antibody-conjugated drugs such as ADC. The invention further relates to a preparation method and application of the antibody molecule and the TROP2xPD-L1 targeting bispecific antibody coupling medicine.
Owner:INNOVENT BIOLOGICS (SUZHOU) CO LTD

Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof

The present invention relates to novel linkers containing a 2,3-disubstituted succinic group, or 2-monosubstituted, or 2,3-disubstituted fumaric or maleic (trans (E)- or cis (Z)-butenedioic), or acetylenedicarboxyl group for conjugation of a cytotoxic agent, and / or one or more different functional molecules per linker to a cell-binding molecule, through bridge linking pairs of thiols on the cell-binding molecule specifically. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders.
Owner:HANGZHOU DAC BIOTECH CO LTD

Immunoconjugates and methods

Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.Ab-[S-L1-L2-L3-L4-L5-L6-L7-D]n   (I)
Owner:IMMUNOME INC